Saudi Journal of Kidney Diseases and Transplantation (Jan 2020)

Leukocytoclastic Vasculitis Associated with Bortezomib Therapy

  • Thiagarajan Raj Yashwanth,
  • Raveendran Vairakkani,
  • Nagalakshmi Dhanapal Srinivasaprasad,
  • Suren Sujith,
  • Kaliaperumal Thirumalvalavan,
  • Mervin Edwin Fernando

DOI
https://doi.org/10.4103/1319-2442.301178
Journal volume & issue
Vol. 31, no. 5
pp. 1106 – 1109

Abstract

Read online

A 28-year-old male, 10 years post live-related renal transplant with stable graft function of 1.4 mg/dL, presented with complaints of loss of appetite and vomiting for three days. On evaluation, he was found to have significant graft dysfunction with a creatinine of 10.3 mg/dL. He was initiated on hemodialysis in view of uremic gastrointestinal symptoms. Graft biopsy done revealed acute cell-mediated rejection BANFF IIB and diffuse C4d-positive antibody-mediated rejection. He was treated with intravenous methylprednisolone, therapeutic plasma exchange, and intravenous immunoglobulin therapy, following which his graft function improved gradually. He received multiple injections of bortezomib as a part of anti-rejection treatment protocol and developed peripheral neuropathy, leukocytoclastic vasculitis, and varicellosis. This case report is to highlight the unusual phenomenon of leukocytoclastic vasculitis in a post renal transplant setting secondary to bortezomib therapy.